Medtronic's (NYSE:MDT) diabetes care business could grow in high-single-digits from $2.4 billion in fiscal 2019 to $2.8 billion in fiscal 2021, according to Trefis estimates. This growth will likely be led by expansion of MiniMed product line in international markets, and continued demand in the ...
Medtronic's (NYSE:MDT) diabetes care business could grow in high-single-digits from $2.4 billion in fiscal 2019 to $2.8 billion in fiscal 2021, according to Trefis estimates. This growth will likely be led by expansion of MiniMed product line in international markets, and continued demand in the ...
Share this Article
Recommended